FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116194535> ?p ?o ?g. }

• W2116194535 endingPage "383" @default.
• W2116194535 startingPage "372" @default.
• W2116194535 abstract "The transcription factor Forkhead box O3 (Foxo3) has a critical role in suppressing the expansion of antigen-specific effector T-cell populations; hence, Foxo3 is a potential target for enhancing the antitumor immunity of cancer vaccines. In this report, we evaluated the potential of RNA interference (RNAi)-mediated silencing of Foxo3 in antigen-presenting cells as an adjuvant for HER2/neu DNA cancer vaccines. Bicistronic plasmids expressing the N-terminal extracellular domain of human HER-2/neu and the Foxo3 short hairpin RNA (hN'-neu-Foxo3 shRNA) or the scrambled control (hN'-neu-scramble shRNA) were subcutaneously injected into mice by gene gun administration to elicit antitumor immunity against p185neu-overexpressing MBT-2 bladder tumor cells. We found that mice treated with hN'-neu-Foxo3 shRNA showed greater reductions in tumor growth and longer survival times than mice treated with hN'-neu-scramble shRNA, indicating that the silencing of Foxo3 enhanced the antitumor efficacy of the HER-2/neu cancer vaccine. Cytotoxicity analyses further revealed that the Foxo3 shRNA-enhanced antitumor effect was associated with significant increases in the number of functional CD8(+) T cells and in the levels of cytotoxic T lymphocytes activity. Interleukin-6 was induced by hN'-neu-Foxo3 shRNA treatment but did not have a critical role in the antitumor effect of the hN'-neu-Foxo3 shRNA vaccine. Moreover, in vivo lymphocyte depletion analyses confirmed that the antitumor efficacy of the hN'-neu-Foxo3 shRNA vaccine depended on functional CD8(+) T cells. Finally, Foxo3 suppression was shown to markedly improve the effect of the HER-2/neu DNA vaccine in limiting the growth and lung metastases of MBT-2 cells. Overall, these results support RNAi-mediated silencing of Foxo3 as an effective strategy to enhance the therapeutic antitumor effect of HER-2/neu DNA vaccines against p185neu-positive tumors." @default.
• W2116194535 created "2016-06-24" @default.
• W2116194535 creator A5010500131 @default.
• W2116194535 creator A5017679925 @default.
• W2116194535 creator A5022579197 @default.
• W2116194535 creator A5049395799 @default.
• W2116194535 creator A5054863079 @default.
• W2116194535 creator A5066547264 @default.
• W2116194535 creator A5069458090 @default.
• W2116194535 creator A5073160048 @default.
• W2116194535 creator A5078382134 @default.
• W2116194535 date "2010-11-25" @default.
• W2116194535 modified "2023-09-26" @default.
• W2116194535 title "RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency" @default.
• W2116194535 cites W1168628786 @default.
• W2116194535 cites W1504403518 @default.
• W2116194535 cites W1516477552 @default.
• W2116194535 cites W1524842363 @default.
• W2116194535 cites W1526621387 @default.
• W2116194535 cites W1773381788 @default.
• W2116194535 cites W1805980869 @default.
• W2116194535 cites W1963416087 @default.
• W2116194535 cites W1970959631 @default.
• W2116194535 cites W1974661803 @default.
• W2116194535 cites W1977958044 @default.
• W2116194535 cites W1978826340 @default.
• W2116194535 cites W1993965822 @default.
• W2116194535 cites W1994048581 @default.
• W2116194535 cites W1996926176 @default.
• W2116194535 cites W2002450099 @default.
• W2116194535 cites W2005664558 @default.
• W2116194535 cites W2007827117 @default.
• W2116194535 cites W2014062759 @default.
• W2116194535 cites W2022725703 @default.
• W2116194535 cites W2030410762 @default.
• W2116194535 cites W2031501484 @default.
• W2116194535 cites W2041026285 @default.
• W2116194535 cites W2042736763 @default.
• W2116194535 cites W2052394178 @default.
• W2116194535 cites W2053931156 @default.
• W2116194535 cites W2059724105 @default.
• W2116194535 cites W2063865728 @default.
• W2116194535 cites W2071810497 @default.
• W2116194535 cites W2078794780 @default.
• W2116194535 cites W2082409488 @default.
• W2116194535 cites W2083022068 @default.
• W2116194535 cites W2086160387 @default.
• W2116194535 cites W2089484109 @default.
• W2116194535 cites W2099113749 @default.
• W2116194535 cites W2112972067 @default.
• W2116194535 cites W2121870317 @default.
• W2116194535 cites W2134390420 @default.
• W2116194535 cites W2135429137 @default.
• W2116194535 cites W2137294107 @default.
• W2116194535 cites W2142116112 @default.
• W2116194535 cites W2142294973 @default.
• W2116194535 cites W2148139455 @default.
• W2116194535 cites W2152864702 @default.
• W2116194535 cites W2153870506 @default.
• W2116194535 cites W2159886660 @default.
• W2116194535 cites W2162195553 @default.
• W2116194535 cites W4251641232 @default.
• W2116194535 doi "https://doi.org/10.1038/gt.2010.146" @default.
• W2116194535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21107437" @default.
• W2116194535 hasPublicationYear "2010" @default.
• W2116194535 type Work @default.
• W2116194535 sameAs 2116194535 @default.
• W2116194535 citedByCount "18" @default.
• W2116194535 countsByYear W21161945352012 @default.
• W2116194535 countsByYear W21161945352013 @default.
• W2116194535 countsByYear W21161945352014 @default.
• W2116194535 countsByYear W21161945352015 @default.
• W2116194535 countsByYear W21161945352016 @default.
• W2116194535 countsByYear W21161945352017 @default.
• W2116194535 countsByYear W21161945352018 @default.
• W2116194535 countsByYear W21161945352019 @default.
• W2116194535 countsByYear W21161945352020 @default.
• W2116194535 countsByYear W21161945352021 @default.
• W2116194535 crossrefType "journal-article" @default.
• W2116194535 hasAuthorship W2116194535A5010500131 @default.
• W2116194535 hasAuthorship W2116194535A5017679925 @default.
• W2116194535 hasAuthorship W2116194535A5022579197 @default.
• W2116194535 hasAuthorship W2116194535A5049395799 @default.
• W2116194535 hasAuthorship W2116194535A5054863079 @default.
• W2116194535 hasAuthorship W2116194535A5066547264 @default.
• W2116194535 hasAuthorship W2116194535A5069458090 @default.
• W2116194535 hasAuthorship W2116194535A5073160048 @default.
• W2116194535 hasAuthorship W2116194535A5078382134 @default.
• W2116194535 hasBestOaLocation W21161945351 @default.
• W2116194535 hasConcept C104317684 @default.
• W2116194535 hasConcept C119056186 @default.
• W2116194535 hasConcept C147483822 @default.
• W2116194535 hasConcept C153911025 @default.
• W2116194535 hasConcept C154317977 @default.
• W2116194535 hasConcept C159047783 @default.
• W2116194535 hasConcept C166703698 @default.
• W2116194535 hasConcept C167508917 @default.
• W2116194535 hasConcept C167672396 @default.

• next